- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001015
A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems
A Multicenter Phase I Clinical Trial of Ribavirin in the Treatment of Patients With AIDS and Advanced AIDS Related Illnesses
To determine the maximum long-term dosage of ribavirin (RBV) that is safe and free of serious side effects in patients with AIDS or AIDS related illnesses. Also, to determine what effect different dosage levels have on biologic markers of efficacy, such as the amount of the AIDS virus (HIV) or number of T cells in the patient's blood.
RBV is a new drug capable of inhibiting the growth of the AIDS virus in the laboratory with little effect on normal human cells. In earlier tests of RBV in AIDS patients, the drug was well tolerated and safe, and this favorable result suggested that RBV should be more extensively studied in patients with AIDS and advanced AIDS related complex (ARC).
Study Overview
Detailed Description
RBV is a new drug capable of inhibiting the growth of the AIDS virus in the laboratory with little effect on normal human cells. In earlier tests of RBV in AIDS patients, the drug was well tolerated and safe, and this favorable result suggested that RBV should be more extensively studied in patients with AIDS and advanced AIDS related complex (ARC).
Patients are selected from three patient groups:
- Patients with AIDS, who have not taken zidovudine (AZT) within 30 days of entry into the study and who have not been discontinued from AZT because of intolerance.
- Patients with AIDS related diseases who have not taken AZT within 30 days of entry into the study, and who have not been discontinued from AZT because of intolerance.
- Patients with AIDS or AIDS related diseases who have had AZT intolerance that required cessation of therapy. This is an outpatient study; patients are seen weekly for the first 4 weeks, every other week through week 12, and then every 4 weeks for the duration of the 24 weeks of the treatment portion of the study. Patients from each of the three diagnostic groups are enrolled at each dose level. For the first 3 days after entry into the study, all patients receive the lowest dose of RBV every 6 hours. Subsequent dosages increase until the maximum tolerated dose (MTD) is reached. The MTD for a group is defined as the dose at which 4 or more of the 8 patients in the group develop toxicity which requires a change or discontinuation of the dosage.
Patients who experience significant toxicity may continue in the study at lower dose to determine the long-term tolerance.
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 921036325
- Univ of California / San Diego Treatment Ctr
-
San Francisco, California, United States, 941102859
- San Francisco AIDS Clinic / San Francisco Gen Hosp
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Harvard (Massachusetts Gen Hosp)
-
-
New York
-
New York, New York, United States, 10016
- Bellevue Hosp / New York Univ Med Ctr
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 275997215
- Univ of North Carolina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
- Short-course therapy (7 days) with oral acyclovir.
- Short-course therapy (7 days) with ketoconazole.
- Topical medications.
- Aerosolized pentamidine for prophylactic purposes.
Concurrent Treatment:
Allowed:
- Blood transfusions for hemoglobin toxicity.
Patients must have two positive HIV p24 antigen tests with titers = or > 70 picograms at least 72 hours apart and within 1 month prior to entry, the last of which must be within 2 weeks of starting therapy.
Prior Medication:
Allowed:
- Zidovudine (AZT), without cessation of therapy required due to intolerance.
- AZT therapy must be discontinued at least 30 days prior to study entry.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- Active opportunistic infection, symptomatic visceral Kaposi's sarcoma (KS) or progression of KS within the month prior to entry into the study, neoplasms other than KS, basal cell carcinoma of the skin, or in situ carcinoma of the cervix. Significant diarrhea, defined as = or > 3 liquid stools per day within the past week.
Concurrent Medication:
Excluded:
- Ongoing systemic therapy and/or prophylaxis for an AIDS-defining opportunistic infection.
- Antineoplastic therapy.
- Other experimental medications.
- Systemic chemoprophylaxis for Pneumocystis carinii pneumonia.
- Chronic (> 7 days) oral acyclovir therapy.
Concurrent Treatment:
Excluded:
- Blood transfusions unless they are for = or > grade 3 hemoglobin toxicity.
Patients with the following are excluded:
- Active opportunistic infection, symptomatic visceral Kaposi's sarcoma (KS) or progression of KS within the month prior to entry into the study, neoplasms other than KS, basal cell carcinoma of the skin, or in situ carcinoma of the cervix. Significant diarrhea, defined as = or > 3 liquid stools per day within the past week.
Prior Medication:
Excluded within 30 days of study entry:
- Antiretroviral agents including zidovudine (AZT).
- Biologic modifiers.
- Systemic corticosteroids.
Prior Treatment:
Excluded within 2 months of study entry:
- Blood transfusion except for those who have taken zidovudine (AZT) who may not have received a transfusion within the previous month.
Active drug or alcohol abuse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
Collaborators and Investigators
Investigators
- Study Chair: Crumpacker C
Publications and helpful links
General Publications
- Crumpacker C, Pearlstein G, van der Horst C, Valentine F, Spector S, Mills J. A phase one increasing dose trial of oral ribavirin (RBV) in patients with AIDS and ARC. Int Conf AIDS. 1990 Jun 20-23;6(3):203 (abstract no SB468)
- Crumpacker C, Cotton D, Pearlstein G, Valentine F, Mills J, Spector S. Ribavirin dose escalating phase 1 trial in patients with AIDS and ARC. Int Conf AIDS. 1989 Jun 4-9;5:336 (abstract no TBP296)
Study record dates
Study Major Dates
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Ribavirin
Other Study ID Numbers
- ACTG 034
- 11010 (DAIDS ES Registry Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Ribavirin
-
Institute of Liver and Biliary Sciences, IndiaTerminated
-
University of Roma La SapienzaCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Hoffmann-La RocheCompletedHealthy VolunteerMexico
-
University of BernRoche Pharma AG; University of Lausanne; University of Basel; Cantonal Hospital... and other collaboratorsCompleted
-
Janssen-Cilag International NVNo longer availableHepatitis CAustralia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
-
Conatus Pharmaceuticals Inc.Completed
-
National Institute of Diabetes and Digestive and...CompletedHepatitis C, ChronicUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedHEAD & NECK CancerUnited States
-
Kaohsiung Medical University Chung-Ho Memorial...Completed